Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:54 PM
Ignite Modification Date:
2025-12-24 @ 9:54 PM
NCT ID:
NCT06560632
Eligibility Criteria:
Inclusion Criteria:
* Male or female participants ≥18 years of age at the time of signing the informed consent
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Participant must have one of the following that has progressed or was non-responsive to prior systemic therapy and for which no standard or available known therapeutic option exists:
1. locally advanced or metastatic epithelial ovarian cancer (including fallopian tube or primary peritoneal), or
2. metastatic breast cancer, or
3. metastatic castration-resistant prostate cancer (mCRPC), or
4. pancreatic adenocarcinoma
* Measurable disease per RECIST v1.1 (exceptions for participants with non-measurable but evaluable disease \[per RECIST and or PSA/CA-125\])
* Next generation sequencing (NGS) report demonstrating eligible tumor biomarker
* Provision of archival tumor tissue, or if adequate archival tumor tissue is not available, provision of a fresh biopsy if there is a lesion that can be safely biopsied
* Acceptable organ function at Screening
* Acceptable hematologic function at Screening
* Life expectancy ≥12 weeks after the start of the treatment according to the Investigator's judgment
Exclusion Criteria:
* History or current condition, therapy, or laboratory abnormality that might confound the study results, or interfere with the patient's participation for the full duration of the study treatment.
* Uncontrolled, symptomatic brain metastases.
* Presence of other known active invasive cancers
* History of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) diagnosis
* Prior therapy with a Polθ inhibitor other than RP-3467
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT06560632
Study Brief:
Protocol Section:
NCT06560632